Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Catalyst Pharm Inc (NQ: CPRX )

12.22 +0.12 (+0.99%)
Streaming Delayed Price Updated: 1:24 PM EDT, Sep 25, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 364,283
Open 12.03
Bid (Size) 12.21 (12)
Ask (Size) 12.22 (4)
Prev. Close 12.10
Today's Range 12.11 - 12.28
52wk Range 11.09 - 22.11
Shares Outstanding 102,780,151
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Catalyst Pharmaceuticals to Participate at the 2023 Cantor Global Healthcare Conference
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Why the growth investor may take a look at NASDAQ:CPRX.
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) may be suited for growth investing, we'll explore why in this article. 
Via Chartmill

Performance

YTD
-32.34%
-32.34%
1 Month
-14.19%
-14.19%
3 Month
-5.27%
-5.27%
6 Month
-25.71%
-25.71%
1 Year
+1.08%
+1.08%

More News

Read More
Vertex Pharmaceuticals Stock Shows Rising Relative Strength, Hits 80+
Via Investor's Business Daily
Catalyst Pharmaceuticals Announces Abstract on Lambert Eaton Myasthenic Syndrome (LEMS) to be Presented at the Upcoming IASLC 2023 World Conference of Lung Cancer
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
5 Analysts Have This to Say About Catalyst Pharmaceuticals
Via Benzinga
Where Catalyst Pharmaceuticals Stands With Analysts
Via Benzinga
ACELYRIN Stock Scores Relative Strength Rating Upgrade; Hits Key Threshold
Via Investor's Business Daily
Axsome Therapeutics Stock Earns Relative Strength Rating Upgrade
Via Investor's Business Daily
Exelixis Stock Sees Rising Relative Strength Rating
Via Investor's Business Daily
Catalyst Pharmaceuticals Announces Multiple Abstracts on FYCOMPA® (Perampanel) from Eisai Co, Ltd., to be Presented at the 35th International Epilepsy Congress
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
The Latest Analyst Ratings for Catalyst Pharmaceuticals
Via Benzinga
Catalyst Pharmaceuticals Reports Strong Second Quarter 2023 Financial Results and Provides Corporate Update
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
7 ‘Strong Buy’ Value Stocks You Should Be Loading Up On Now
Via InvestorPlace
Patrick J. McEnany Announces Intention to Retire as CEO of Catalyst Pharmaceuticals by Year-End
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 9, 2023
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals Acquires Exclusive North American License For Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
7 Little-Known Stocks to Buy Now Before They Become the Next Big Thing
Via InvestorPlace
ETF Returns: Mid-Cap Winners And Losers
Via Benzinga
Truist Securities Maintains Buy Rating for Catalyst Pharmaceuticals: Here's What You Need To Know
Via Benzinga
Catalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
The 7 Best Stocks Under $15 to Buy in June 2023
Via InvestorPlace
Catalyst Pharmaceuticals Reports Positive Momentum in Second Quarter 2023
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals Appoints Tamar Thompson to its Board of Directors
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Down 19% in 1 Day, Is Catalyst Pharmaceuticals a Smart Contrarian Buy?
Via The Motley Fool
Ultragenyx Pharm Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.